Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Diabetic Nephropathy

Interventions

DRUG

Topiroxostat BID, (Oral daily dosing for 28 weeks)

The dose of topiroxostat is increased up to 160 mg/day in a stepwise manner.

DRUG

Placebo BID, (Oral daily dosing for 28 weeks)

Subjects randomized to the placebo arm will receive placebo.

Trial Locations (1)

Sanwa Kagaku Kenkyusho Co., Ltd., Nagoya